Cathelicidin Antimicrobial Peptide Has Opposite Effects on MS Depending on Which Cells Produce It
In a mouse model of multiple sclerosis, cathelicidin (CRAMP) produced by neutrophils worsened neuroinflammation, while cathelicidin produced by neurons was protective — revealing cell-type-specific roles for this antimicrobial peptide in autoimmune brain disease.
Quick Facts
What This Study Found
Cathelicidin antimicrobial peptide has antagonistic roles in neuroinflammation: neutrophil-derived CRAMP promotes disease in EAE, while neuron-derived CRAMP is protective, demonstrating cell-type-specific immunomodulation.
Key Numbers
CRAMP produced by CNS-recruited neutrophils at early stage; expressed by neurons with opposing effects on inflammation.
How They Did This
Animal study using EAE (experimental autoimmune encephalomyelitis) mouse model of multiple sclerosis. Investigated cathelicidin (CRAMP) expression in CNS-recruited neutrophils and neurons, and assessed effects on disease progression.
Why This Research Matters
Multiple sclerosis has no cure, and understanding what drives neuroinflammation is key to finding one. This study reveals that antimicrobial peptides — traditionally thought of as infection fighters — play complex, context-dependent roles in autoimmune brain disease.
The Bigger Picture
This finding challenges the simplistic view of antimicrobial peptides as purely defensive molecules. In autoimmune diseases like MS, the same peptide can be both harmful and helpful — suggesting that targeted therapies would need to block neutrophil cathelicidin while preserving neuronal production.
What This Study Doesn't Tell Us
Mouse model (EAE) — may not fully replicate human MS. CRAMP (mouse) may have different properties than LL-37 (human cathelicidin). Mechanisms underlying the opposite effects not fully characterized. Translation to therapeutic approaches is unclear.
Questions This Raises
- ?Is LL-37 (human cathelicidin) similarly antagonistic in human MS — harmful from neutrophils, protective from neurons?
- ?Could blocking neutrophil cathelicidin be a therapeutic strategy for MS without affecting neuronal protection?
- ?Do other antimicrobial peptides show similar cell-type-dependent effects in autoimmune diseases?
Trust & Context
- Key Stat:
- Same peptide, opposite effects Neutrophil cathelicidin worsens EAE while neuronal cathelicidin protects against it
- Evidence Grade:
- Moderate evidence — well-designed animal study with mechanistic insight. EAE is an established MS model but doesn't capture all aspects of human disease.
- Study Age:
- Published in 2024. Adds to the growing understanding of antimicrobial peptides' immunomodulatory roles beyond infection.
- Original Title:
- Cathelicidin antimicrobial peptide expression in neutrophils and neurons antagonistically modulates neuroinflammation.
- Published In:
- The Journal of clinical investigation, 135(3) (2024)
- Authors:
- Verma, Subash Chand(2), Enée, Emmanuelle, Manasse, Kanchanadevi, Rebhi, Feriel, Penc, Axelle, Romeo-Guitart, David, Bui Thi, Cuc, Titeux, Matthias, Oury, Franck, Fillatreau, Simon, Liblau, Roland, Diana, Julien
- Database ID:
- RPEP-09436
Evidence Hierarchy
Frequently Asked Questions
How can the same peptide both cause and prevent brain inflammation?
It depends on which cells make it. When immune cells called neutrophils rush to the brain and release cathelicidin, it ramps up inflammation. But when brain neurons produce the same peptide, it actually calms inflammation down. The cellular context completely changes the peptide's effect.
Could this help treat multiple sclerosis?
Potentially — if we could block cathelicidin from inflammatory immune cells while keeping the brain neurons' protective production intact, it might be a new way to reduce MS-related brain damage. However, this has only been shown in mice so far and needs much more research.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09436APA
Verma, Subash Chand; Enée, Emmanuelle; Manasse, Kanchanadevi; Rebhi, Feriel; Penc, Axelle; Romeo-Guitart, David; Bui Thi, Cuc; Titeux, Matthias; Oury, Franck; Fillatreau, Simon; Liblau, Roland; Diana, Julien. (2024). Cathelicidin antimicrobial peptide expression in neutrophils and neurons antagonistically modulates neuroinflammation.. The Journal of clinical investigation, 135(3). https://doi.org/10.1172/JCI184502
MLA
Verma, Subash Chand, et al. "Cathelicidin antimicrobial peptide expression in neutrophils and neurons antagonistically modulates neuroinflammation.." The Journal of clinical investigation, 2024. https://doi.org/10.1172/JCI184502
RethinkPeptides
RethinkPeptides Research Database. "Cathelicidin antimicrobial peptide expression in neutrophils..." RPEP-09436. Retrieved from https://rethinkpeptides.com/research/verma-2024-cathelicidin-antimicrobial-peptide-expression
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.